MelanomaArchives
Successful use of nivolumab and relatlimab as salvage therapy for metastatic uveal melanoma.
Melanoma 1 min.
Identification of effective systemic therapies for the treatment of metastatic uveal melanoma remains an ongoing challenge. While immune checkpoint inhibitors are frequently used to treat this disease, response rates and survival outcomes remain poor. In this case report, we present two heavily pretreated...
Evaluating the Diagnostic Concordance of MyPath Melanoma Assay and PRAME Immunohistochemistry in Challenging Melanocytic Lesions.
Melanoma 1 min.
The 23-gene expression signature (GES) assay (myPath Melanoma) is a well-established molecular test for analyzing challenging melanocytic lesions, alongside fluorescence in situ hybridization (FISH) and single nucleotide polymorphism (SNP) array. However, routine use of these tests is often limited by...
Primary Cutaneous Melanoma With Sebocyte-like Melanocytes: Case Report and Review of the Literature.
Melanoma 1 min.
Melanocytes with clear vacuolated cytoplasm and scalloped nuclei, resembling mature sebocytes, can occur in congenital, acquired, and blue melanocytic nevi but are rare in malignant melanomas. A case of primary cutaneous melanoma with sebocyte-like cells is reported. The patient was a 75-year-old male...
METTL9 as a protein biomarker predicts the prognosis and immunotherapy response of skin-cutaneous melanoma.
Melanoma 1 min.
The role of methyltransferase-like proteins (METTLs) in skin cutaneous melanoma (SKCM) remains unclear. This study investigates the expression of METTLs, particularly METTL9, in SKCM and its clinical significance. Through multiple database analyses and immunohistochemical experiments, we found that METTL9...
